[1. Tripodi A. The Long-Awaited Whole-Blood Thrombin Generation Test. Clin Chem. 2012;58(8):1173-5. DOI: 10.1373/clinchem.2012.18926610.1373/clinchem.2012.18926622685127]Search in Google Scholar
[2. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, et al. The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32:249-53. DOI: 10.1159/00007357510.1159/00007357513679651]Search in Google Scholar
[3. Marcus D Lance. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Lance Thrombosis J. 2015;13:1. DOI: 10.1186/1477-9560-13-110.1186/1477-9560-13-1441720425937820]Search in Google Scholar
[4. Kern A, Varnai K, Vasarhelyi B. Thrombin generation assays and their clinical application. Orv Hetil. 2014; 155 (22):851-7. DOI: 10.1556/OH.2014.2989910.1556/OH.2014.2989924860049]Search in Google Scholar
[5. Young G, Sorensen B, Dargaud Y, Negrier C, Brummel- Ziedins K, Nigel S, et al. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013; 121 (11):1944-50. DOI: 10.1182/ blood-2012-08-37893510.1182/blood-2012-08-378935364505423319573]Search in Google Scholar
[6. Mancuso ME, Fasulo MR. Thrombin Generation Assay as a Laboratory Monitoring Tool during Bypassing Therapy in Patients with Hemophilia and Inhibitors. Semin Thromb Haemost. 2016;42:30-5.]Search in Google Scholar
[7. Mancuso ME, Chantaragkul V, Clerici M. Low thrombin generation during major orthopedic surgery fails to predict bleeding risk in inhibitor patients treated with bypassing agents. Haemophilia. 2016;22(4):292-30. DOI: 10.1111/hae.1293910.1111/hae.1293927197961]Search in Google Scholar
[8. Turecek PL, Varadi K, Keil B, Negrier C, Berntorp E, Astermark J, et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb. 2003;33 (1):16-22. DOI: 10.1159/00007163710.1159/00007163712853708]Search in Google Scholar
[9. Dargaud Y, Lienhart A, Meunier S, Hequet O, Chavanne H, Chamouard V, et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia.2005;11(5):552-8. DOI: 10.1111/j.1365-2516.2005.01141.x10.1111/j.1365-2516.2005.01141.x16128902]Search in Google Scholar
[10. 1Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood. 2010; 116 (25):5734-7. DOI: 10.1182/blood-2010-06-29190610.1182/blood-2010-06-29190620810929]Search in Google Scholar
[11. Mancuso ME, Chantarangkul V, Clerici M. Thrombin generation assay in hemophilic patients with or without inhibitors undergoing orthopedic surgery. Haemophilia. 2014; 20 (3):10.]Search in Google Scholar
[12. Instrumentation laboratory ACL ELITE* / ELITE PRO System. Reagents, controls and calibrators package’s inserts. PN 722277 Rev. BB (November 2010) Beckman Coulter, Inc.]Search in Google Scholar
[13. Shima M, Matsumoto T, Ogiwara K New assays for monitoring haemophilia treatment. Haemophilia. 2008;3:83-92. DOI: 10.1111/j.1365-2516.2008.01737.x10.1111/j.1365-2516.2008.01737.x18510527]Search in Google Scholar
[14. Ninivaggi M, Apitz-Castro R, Dargaud Y, de Laat B, Coenraad Hemker H, Lindhout T, et al. Whole- Blood Thrombin Generation Monitored with a Calibrated Automated Thrombogram-Based Assay. Clin Chem. 2012; 58 (8):1252-9. DOI: 10.1373/ clinchem.2012.18407710.1373/clinchem.2012.18407722665918]Search in Google Scholar
[15. Mahlangu J, Kuliczkowski K, Karim FA, Stasyshyn O, Kosinova MV, Lepatan LM, et al. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016; 128 (5): 630-637. DOI: 10.1182/blood-2016-01-68743410.1182/blood-2016-01-687434497419827330001]Search in Google Scholar
[16. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia. 2005; 11 (1):1-6. DOI: 10.1111/j.1365-2516.2005.01156.x10.1111/j.1365-2516.2005.01156.x16219042]Search in Google Scholar
[17. Négrier C, Gomperts ED, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia. 2006;12:4-13. DOI: 10.1111/j.1365-2516.2006.01379.x10.1111/j.1365-2516.2006.01379.x]Search in Google Scholar
[18. Dargaud Y, Prevost C, Lienhart A, Bordet JC, Negrier C. Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots. Haemophilia. 2011;17:957-61. DOI: 10.1111/j.1365-2516.2011.02526.x10.1111/j.1365-2516.2011.02526.x21453422]Search in Google Scholar
[19. Vila V, Aznar JA, Moret A, Marco A, Navarro S, Vila C, et al. Assessement of the thrombin generation assay in haemophilia: comparative study between fresh and frozen platelet-rich plasma. Haemophilia. 2013;19:318-21. DOI: 10.1111/hae.1204410.1111/hae.1204423174035]Search in Google Scholar
[20. Perrin J, Depasse P, Lecompte T. Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalization with an external reference plasma. Thromb Res. 2016;135(1):125-130. 10.1016/j.thromres.2014.12.01525563679]Search in Google Scholar